tedisamil

08/01/1999 - "We herein report the efficacy of tedisamil in terminating and protecting against the reinduction of atrial flutter (AFL) in a conscious canine model. "
08/01/1999 - "Tedisamil in a chronic canine model of atrial flutter."
07/07/2004 - "Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter."
07/07/2004 - "The goal of the present study was to assess the efficacy and safety of intravenous tedisamil, a new antiarrhythmic compound, for conversion of recent-onset atrial fibrillation (AF) or atrial flutter (AFL) to normal sinus rhythm (NSR). "
01/01/2001 - "Tedisamil is anti-arrhythmic in animal models of ventricular arrhythmias and atrial flutter. "

06/01/2003 - "Hence, the double properties of tedisamil as a drug that both inhibits atrial fibrillation and acts in an anti-ischemic mode are an attractive basis for future clinical research."
06/01/2003 - "Tedisamil works acutely against atrial fibrillation. "
10/01/2001 - "There are no reports to date evaluating tedisamil's efficacy in terminating atrial fibrillation (AF). "
01/01/2001 - "Tedisamil also rapidly terminated sustained atrial fibrillation and prevented its reinitiation in a canine model of the condition [315378]. "
07/07/2004 - "Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter."

01/01/1998 - "Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation."
08/22/2003 - "New class III antiarrhythmic/defibrillating compound tedisamil was shown to facilitate termination of atrial and ventricular fibrillation in experimental as well as clinical conditions. "
02/01/1997 - "Tedisamil increases both spatial coherence and temporal regularity of ventricular fibrillation. "
02/01/1997 - "We measured magnitude-squared coherence, a measure of spatial organization, and ventricular fibrillation (VF) cycle length, ventricular effective refractory period (VERP), and monophasic action potential duration (APD90) as well as defibrillation energy threshold (E50) at baseline and after 150 micrograms/kg of tedisamil (n = 13) or saline control (n = 6) in an open chest dog model. "
02/01/1997 - "Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements."

02/01/2004 - "Phase III studies in patients with ischaemic heart disease indicated that tedisamil is an effective agent for the treatment of angina, resulting in a dose-dependent increase in anginal threshold (with a decrease in anginal attacks, increased exercise capacity during treadmill exercise and decreased electrocardiographic signs of exercise induced ischaemia) in comparison to placebo. "
07/01/2001 - "This study was undertaken to characterize the effects of tedisamil on isolated rat cardiovascular tissues, and identify actions that could be beneficial or detrimental in the treatment of cardiac disease. "
02/01/2004 - "Subsequent Phase II results have confirmed that in patients with ischaemic heart disease, tedisamil had beneficial haemodynamic and anti-ischaemic effects. "
01/01/2001 - "A drug that is bradycardic without increasing blood pressure would be an improvement on tedisamil as the master switch of nature for ischaemic heart disease."

07/01/2001 - "The positive inotropic and negative chronotropic effects of tedisamil in the rat, which are partially or fully maintained in hypertrophied or failing myocardium would be beneficial in the treatment of heart failure. "
12/01/1998 - "Accordingly, this study was designed to investigate the hemodynamic effect of the novel bradycardic compound tedisamil in patients with heart failure. "
01/01/2001 - "In heart failure patients, tedisamil reduces heart rate, but increases blood pressure. "
12/01/1998 - "In these patients, tedisamil increased vascular resistance, which is unwanted in the treatment of congestive heart failure."
12/01/1998 - "Cardiac and hemodynamic effects of the sinus node inhibitor tedisamil dihydrochloride in patients with congestive heart failure due to dilated cardiomyopathy."